source
- Argenx to acquire Forte Biosciences for $2.2 billion, securing phase-2 vitiligo antibody FB102Argenx announced it will buy Forte Biosciences for $2.2 billion, gaining access to FB102, an anti‑CD122 antibody currently in phase‑2 trials for vitiligo and celiac disease. In a recent phase 1b s…
- PhRMA pushes back as prescription drug spending continues to rise, according to STAT+ newsletterSTAT+ Health Care Inc. newsletter author Bob Herman reports on the growing concern that prescription drug spending is rising despite industry attempts to downplay it. The piece appears in the July…